Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy
Patients with ovarian clear-cell carcinoma have limited treatment choices, because they are resistant to the standard chemotherapeutic agents used in ovarian cancer. The phase II KEYNOTE-100 trial revealed that pembrolizumab monotherapy demonstrated a 15.8% objective response in patients with ovaria...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591060710195200 |
|---|---|
| author | Cheng-Wei Huang Ruo-Han Tseng |
| author_facet | Cheng-Wei Huang Ruo-Han Tseng |
| author_sort | Cheng-Wei Huang |
| collection | DOAJ |
| description | Patients with ovarian clear-cell carcinoma have limited treatment choices, because they are resistant to the standard chemotherapeutic agents used in ovarian cancer. The phase II KEYNOTE-100 trial revealed that pembrolizumab monotherapy demonstrated a 15.8% objective response in patients with ovarian clear-cell carcinoma in the subgroup analysis, which is much higher than that of other histology subtypes of ovarian cancer. Immune checkpoint inhibitors may play a new role in the treatment of these malignancies. Genetic analyses revealed a significant proportion of ovarian clear-cell carcinoma carrying the AT-rich interaction domain 1A protein (ARID1A) mutation. The association between a higher frequency of ARID1A mutation and a higher response to immune checkpoint inhibitors in ovarian clear-cell carcinoma opens a new research topic. Herein, we report a patient with ovarian clear-cell carcinoma refractory to platinum-based chemotherapy, who was treated with a reduced dose of bevacizumab and pembrolizumab combination therapy and achieved a complete treatment response. |
| format | Article |
| id | doaj-art-cdfd8238cc844203892851502df3c028 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-cdfd8238cc844203892851502df3c0282025-01-23T05:11:18ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062024-01-01111495210.4103/ejcrp.eJCRP-D-23-00035Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to ChemotherapyCheng-Wei HuangRuo-Han TsengPatients with ovarian clear-cell carcinoma have limited treatment choices, because they are resistant to the standard chemotherapeutic agents used in ovarian cancer. The phase II KEYNOTE-100 trial revealed that pembrolizumab monotherapy demonstrated a 15.8% objective response in patients with ovarian clear-cell carcinoma in the subgroup analysis, which is much higher than that of other histology subtypes of ovarian cancer. Immune checkpoint inhibitors may play a new role in the treatment of these malignancies. Genetic analyses revealed a significant proportion of ovarian clear-cell carcinoma carrying the AT-rich interaction domain 1A protein (ARID1A) mutation. The association between a higher frequency of ARID1A mutation and a higher response to immune checkpoint inhibitors in ovarian clear-cell carcinoma opens a new research topic. Herein, we report a patient with ovarian clear-cell carcinoma refractory to platinum-based chemotherapy, who was treated with a reduced dose of bevacizumab and pembrolizumab combination therapy and achieved a complete treatment response.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00035angiogenesis inhibitorat-rich interaction domain 1aimmune checkpoint inhibitorovarian clear-cell carcinoma |
| spellingShingle | Cheng-Wei Huang Ruo-Han Tseng Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy Journal of Cancer Research and Practice angiogenesis inhibitor at-rich interaction domain 1a immune checkpoint inhibitor ovarian clear-cell carcinoma |
| title | Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy |
| title_full | Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy |
| title_fullStr | Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy |
| title_full_unstemmed | Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy |
| title_short | Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy |
| title_sort | promising remission with reduced bevacizumab and pembrolizumab dosage in a patient with at rich interaction domain 1a mutated ovarian clear cell carcinoma refractory to chemotherapy |
| topic | angiogenesis inhibitor at-rich interaction domain 1a immune checkpoint inhibitor ovarian clear-cell carcinoma |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00035 |
| work_keys_str_mv | AT chengweihuang promisingremissionwithreducedbevacizumabandpembrolizumabdosageinapatientwithatrichinteractiondomain1amutatedovarianclearcellcarcinomarefractorytochemotherapy AT ruohantseng promisingremissionwithreducedbevacizumabandpembrolizumabdosageinapatientwithatrichinteractiondomain1amutatedovarianclearcellcarcinomarefractorytochemotherapy |